{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=40",
    "query": {
      "intervention": "Formulation #2",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 1745,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T13:52:44.275Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04143659",
      "title": "A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Women",
        "Female Contraception"
      ],
      "interventions": [
        {
          "name": "levonorgestrel butanoate (LB) injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Premier Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2020-03-03",
      "completion_date": "2026-03-26",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 7,
      "location_summary": "Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04143659"
    },
    {
      "nct_id": "NCT00800280",
      "title": "Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "PD 0332334",
          "type": "DRUG"
        },
        {
          "name": "cimetidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-01",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2010-02-17",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800280"
    },
    {
      "nct_id": "NCT04705922",
      "title": "Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TT-00420 Capsule",
          "type": "DRUG"
        },
        {
          "name": "TT-00420 Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransThera Sciences (Nanjing), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-12-29",
      "completion_date": "2021-07-23",
      "has_results": false,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04705922"
    },
    {
      "nct_id": "NCT02605122",
      "title": "Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Community-acquired Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Solithromycin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Months to 17 Years"
      },
      "enrollment_count": 97,
      "start_date": "2016-04",
      "completion_date": "2018-03-21",
      "has_results": true,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 21,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605122"
    },
    {
      "nct_id": "NCT00436826",
      "title": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Interferon-beta (IFN-beta)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 172,
      "start_date": "2006-11-30",
      "completion_date": "2012-03-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 21,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436826"
    },
    {
      "nct_id": "NCT02414165",
      "title": "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Toca 511",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Toca FC",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Tocagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 403,
      "start_date": "2015-11-30",
      "completion_date": "2019-12-20",
      "has_results": false,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 50,
      "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02414165"
    },
    {
      "nct_id": "NCT06948084",
      "title": "Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Daratumumab and Recombinant Human Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2027-05-22",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 32,
      "location_summary": "Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 23 more",
      "locations": [
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Post Falls",
          "state": "Idaho"
        },
        {
          "city": "Sandpoint",
          "state": "Idaho"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06948084"
    },
    {
      "nct_id": "NCT03101293",
      "title": "A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-831",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-04-04",
      "completion_date": "2017-05-26",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03101293"
    },
    {
      "nct_id": "NCT02616484",
      "title": "Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pyruvate Dehydrogenase Complex Deficiency"
      ],
      "interventions": [
        {
          "name": "Dichloroacetate (DCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Genotype",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Saol Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-07-14",
      "completion_date": "2025-08-27",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 10,
      "location_summary": "Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616484"
    },
    {
      "nct_id": "NCT02930902",
      "title": "Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Resectable Pancreatic Carcinoma",
        "Stage I Pancreatic Cancer AJCC v6 and v7",
        "Stage IA Pancreatic Cancer AJCC v6 and v7",
        "Stage IB Pancreatic Cancer AJCC v6 and v7",
        "Stage II Pancreatic Cancer AJCC v6 and v7",
        "Stage IIA Pancreatic Cancer AJCC v6 and v7",
        "Stage IIB Pancreatic Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-02-20",
      "completion_date": "2023-01-03",
      "has_results": false,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-11-06T13:52:44.275Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930902"
    }
  ]
}